Wave Life Sciences stock: Mizuho reiterates Outperform at USD 23
Published on 11/22/2026 at 13:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMizuho flags clinical catalysts
- Mizuho reiterated an Outperform rating and a USD 23 price target for Wave Life Sciences.
- The firm expects fourth-quarter WVE-006 data to guide dose and interval decisions in alpha-1 antitrypsin deficiency.
- Mizuho sees WVE-007 as a 2027 catalyst and expects a WVE-008 clinical trial application in the fourth quarter of 2026.
Wave Life Sciences received a renewed Outperform rating from Mizuho on Friday, November 20, with a USD 23 price target. Investing.com reported that the firm cited positive regulatory alignment for the company's alpha-1 antitrypsin deficiency program and identified the INHBE program as a potential driver.
Clinical milestones shape the view
Mizuho expects fourth-quarter 2026 data from monthly 600 mg multidose testing of WVE-006 to inform pivotal dose and interval decisions. Wave is planning a single two-year registrational study with a one-year interim analysis that could support a potential accelerated-approval route.
The firm views WVE-007, which targets INHBE, as more important for 2027. Mizuho also expects Wave to submit a clinical trial application for WVE-008, an RNA-editing program targeting PNPLA3 I148M liver disease, in the fourth quarter of 2026.
Wave Life Sciences company facts
- Company: Wave Life Sciences, Inc.
- ISIN: US94352A1043
- Ticker: WVE
- Home exchange: Nasdaq
Wave Life Sciences trades within the broader U.S. equity market, tracked through the S&P 500.
